"Bharat Biotech International Limited (BBIL), a global leader in vaccine innovation and developer of vaccines for infectious diseases, today dedicated iNCOVACC® (BBV154) to the nation, the world's 1st COVID intranasal vaccine for Primary series and Heterologous booster," read a release issued by the firm on Thursday.
January 26, 2023The Union Health Ministry said that those who have taken Covishield and Covaxin could take the nasal vaccine as a heterologous booster dose. The iNCOVACC has been approved by the Government of India and will be used as a heterologous booster dose for those above 18 years of age.
December 27, 2022The nasal vaccine BBV154 had received approval from the Drugs Controller General of India in November for restricted use in an emergency situation for those above 18 as a heterologous booster dose.
December 23, 2022The nassal vaccine has been approved for those aged above 18 years. The vaccine will be available in the private hospitals for booster dose in the initial phase.
December 23, 2022Ella, Chairman, and MD of Bharat Biotech, which produces Covaxin, met state Minister for Large and Medium Industries Dr. Murugesh R. Nirani, in Hyderabad on Friday, stated the official press release from the ministry of large and medium industries.
October 14, 2022The new inoculation was developed by Bharat Biotech, which had already developed an intravenous product greenlit by the World Health Organization last November.
September 7, 2022India's first intranasal Covid vaccine by Bharat Biotech on Tuesday got the approval from the Drug Controller General of India for 18+ age group for restricted use in emergency situation.
September 6, 2022The WHO's EUL approval for Covaxin was expected by 5 October as WHO's Strategic Advisory Group of Experts on Immunization (SAGE) was scheduled to meet on this day to make its recommendations on Bharat Biotech's Covaxin for Emergency Use Listing. The process has been delayed as more technical data has been sought from the pharma major.
September 28, 2021The National Covid-19 Vaccination Programme has been successfully going on across all states and Union Territories since 16th January, 2021, he added.
August 29, 2021In order to augment the Covid-19 vaccine production capacity in the country, the Central government in April requested that the IIL and Bharat Biotech International Ltd (BBIL) join hands.
August 13, 2021The new variant of Rotavac is a unique rotavirus vaccine formulation that can be administered without a buffer. Its low dose volume (0.5 ml) facilitates easy vaccine logistics, cold chain management and low biomedical waste disposal post-vaccination. It is used for the prevention of rotavirus infection, which is prevalent in infants and young children.
August 2, 2021Bharat Biotech chairman and managing director, Krishna Ella, said all documents required for EUL of Covaxin, have been submitted to WHO as of July 9.
July 12, 2021So far, Covaxin's supply has roughly contributed only 10 per cent of the total doses administered in the nationwide Covid-19 immunisation programme.
July 10, 2021The company's co-founder and joint managing director Suchitra Ella on Wednesday tweeted that Andhra Pradesh, Assam, Delhi, Gujarat, Karnataka, Madhya Pradesh, Maharashtra, Tamil Nadu, and Telangana were supplied the vaccines through the government of India from June 8 to 14.
June 16, 2021The Hyderabad-based vaccine manufacturing company said a higher price in private markets is required to offset part of the costs.
June 15, 2021The media reports suggested that the last order placed with the two vaccine makers (100 million doses with SII and 20 million doses with Bharat Biotech) was in March.
May 3, 2021Serum Institute on Wednesday slashed the price of its Covishield vaccine to Rs 300 per dose from the earlier Rs 400 for states.
April 30, 2021